Lung cancer remains a leading cause cancer death worldwide. Current standard of care, screening based on Low-Dose Computed Tomography (LDCT), has improved early detection, yet false positives and late-stage diagnoses persist. CADe/CADx SaMD enables earlier lung cancer detection & characterization, reduces invasive and useless procedures, and delivers meaningful cost savings for US payers. These findings advocate for integrating CADe/CADx SaMD into routine lung cancer screening programs.

Poster présenté au Congrès ISPOR US 2025 à Montréal, Canada.